Who are AGN-210669's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Capsaicin Topical Cream, CBD, Cannabidiol Oral Product, Capsaicin 8%, dl-Methylphenidate plus Cannabidiol, Potassium Nitrate 2%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agn-210669.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AGN-210669 — Competitive Intelligence Brief

AGN-210669 (AGN-210669) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TRPV1 antagonist. Area: Pain Management.

phase 2 TRPV1 antagonist TRPV1 Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

AGN-210669 (AGN-210669) — Allergan. AGN-210669 is a selective inhibitor of the transient receptor potential vanilloid 1 (TRPV1) channel that reduces pain signaling in sensory neurons.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AGN-210669 TARGET	AGN-210669	Allergan	phase 2	TRPV1 antagonist	TRPV1
Capsaicin Topical Cream	Capsaicin Topical Cream	Women and Infants Hospital of Rhode Island	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
CBD	CBD	Stero Biotechs Ltd.	marketed	Cannabinoid	5-HT1A, TRPV1, GPR55, CB1 (allosteric), CB2 (allosteric)
Cannabidiol Oral Product	Cannabidiol Oral Product	University of Connecticut	marketed	Cannabinoid	Multiple targets including CB1/CB2 (allosteric modulation), 5-HT1A receptor, TRPV1 channel
Capsaicin 8%	Capsaicin 8%	Averitas Pharma, Inc.	marketed	Topical analgesic; TRPV1 agonist	TRPV1 (transient receptor potential vanilloid 1)
dl-Methylphenidate plus Cannabidiol	dl-Methylphenidate plus Cannabidiol	University of Florida	marketed	Combination therapy: sympathomimetic amine plus phytocannabinoid	Dopamine transporter, norepinephrine transporter (methylphenidate); CB1/CB2 receptors, 5-HT1A, TRPV1 (cannabidiol)
Potassium Nitrate 2%	Potassium Nitrate 2%	Federal University of Uberlandia	marketed	Desensitizing agent	Nitric oxide pathway; sensory nerve fibers (TRPV1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TRPV1 antagonist class)

Allergan · 1 drug in this class
Grünenthal GmbH · 1 drug in this class
Kissei Pharmaceutical Co., Ltd. · 1 drug in this class
Teva Branded Pharmaceutical Products R&D LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AGN-210669 — Competitive Intelligence Brief. https://druglandscape.com/ci/agn-210669. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab